Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01937455
Recruitment Status : Unknown
Verified January 2018 by International AIDS Vaccine Initiative.
Recruitment status was:  Active, not recruiting
First Posted : September 9, 2013
Last Update Posted : January 11, 2018
National Institute of Allergy and Infectious Diseases (NIAID)
Children's Hospital of Philadelphia
Information provided by (Responsible Party):
International AIDS Vaccine Initiative

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.

Condition or disease Intervention/treatment Phase
HIV Infections Biological: rAAV1-PG9DP Phase 1

Detailed Description:

This study is a phase 1, randomized, blinded, dose-escalation study to evaluate the safety and tolerability of rAAV1-PG9DP when administered intramuscularly at 4x10^12 vg, 4x10^13 vg, 8x10^13 vg and 1.2x10^14 vg in healthy male adults.

Volunteers will be screened up to 42 days before injection and will be followed for 12 months after the single administration. It is anticipated that it will take approximately 13 months to enroll the study.

Volunteers will be randomly assigned investigational product (IP) or placebo within each of the dose groups described in the study design table above depending on which group is enrolling. Study staff and volunteers will be blinded only with respect to the allocation of placebo or IP. Blinding will not apply to the assignment of dosage levels.

Volunteers will be offered enrollment into a follow-up study at the research center when they have finished participating in the trial

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
Study Start Date : September 2014
Estimated Primary Completion Date : February 2018
Estimated Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Group A
rAAV1-PG9DP or placebo (v:p = 3:1)
Biological: rAAV1-PG9DP
4x10^12 vg administered intramuscularly

Experimental: Group B
rAAV1-PG9DP or placebo (v:p = 3:1)
Biological: rAAV1-PG9DP
4x10^13 vg administered intramuscularly

Experimental: Group C/C1
rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
Biological: rAAV1-PG9DP
8x10^13 vg administered intramuscularly

Experimental: Group D/D1
rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
Biological: rAAV1-PG9DP
1.2x10^14 vg administered intramuscularly

Primary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: 12 months ]
    1. Proportion of volunteers with moderate or greater reactogenicity (i.e., solicited adverse events) during a 7 day follow-up period after the injection
    2. Proportion of volunteers with moderate or greater adverse events (i.e. unsolicited adverse events) including safety laboratory (biochemical, haematological) parameters, from the day of the injection up to 180 days post injection
    3. Proportion of volunteers with serious adverse events (SAEs) related to the IMP throughout the study period
    4. The proportion of volunteers in each group with Adverse Event of Special Interest, defined as adverse events potentially caused by antigen-antibody complexes or immune responses directed to cells producing the transgene

Secondary Outcome Measures :
  1. Pharmacokinetics and Immunogenicity [ Time Frame: 12 months ]
    To assess (qualitative and quantitative) immune responses elicited by the different dose levels.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male.
  2. 18 to 45 years of age.
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  4. In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and has provided informed consent.
  5. Willing to undergo HIV testing, risk reduction counseling and receive HIV test results.
  6. All sexually active males must be willing to use male condoms with all sexual partners (female or male) from the day of first injection until 3 months after the injection.
  7. Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV-positive due to vaccine-induced antibodies, until the anti-HIV antibody titers become undetectable.

Exclusion Criteria:

  1. Confirmed HIV-1 or HIV-2 infection.
  2. Any clinically relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the investigator within the previous 6 months.
  3. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator makes the volunteer unsuitable for participation in the study.
  4. Any of the following specific risk behaviour for HIV infection within 6 months prior to injection:

    • Unprotected sexual intercourse with a known HIV infected person or a partner known to be at high risk for HIV infection or a casual partner (i.e., no continuing established relationship)
    • Unprotected anal intercourse with another man (either insertive or receptive)
    • Three or more sexual partners
    • Engaged in sex work
    • Frequent excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of illicit drugs
    • History of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, HSV-2, chlamydia, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B
  5. Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions).
  6. Clinically significant laboratory abnormalities.
  7. Anti-AAV1 antibody level above the cut-off.
  8. Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after injection with IP; or receipt of other vaccine within the previous 14 days or planned receipt within 14 days after injection with IP (exception is live attenuated influenza vaccine within 14 days).
  9. Receipt of blood transfusion or blood-derived products within the previous 3 months.
  10. Participation in another clinical trial of an IMP currently, within the previous 3 months or expected participation during this study.
  11. Prior receipt of another AAV vector, investigational HIV vaccine candidate, monoclonal antibody or polyclonal immunoglobulin (note: receipt of placebo in a previous HIV vaccine or monoclonal antibody trial will not exclude a volunteer from participation).
  12. History of severe local or systemic reactogenicity to vaccines or infusions (e.g., anaphylaxis, respiratory difficulties, angioedema)
  13. Psychiatric condition that compromises safety of the volunteer and precludes compliance with the protocol.
  14. In the opinion of the Principal Investigator, it is not in the best interest of the volunteer to participate in the trial.
  15. Seizure disorder: a participant who has had a seizure in the last 3 years.
  16. ECG with clinically significant findings or features.
  17. History of, or known active cardiovascular disease.
  18. Have 3 or more of the following risk factors:

    • Hypertension diagnosed by a doctor
    • Hypercholesterolemia diagnosed by a doctor
    • Diabetes mellitus
    • Hyperglycemia diagnosed by a doctor
    • First degree relative (i.e., mother, father, brother, sister) who had a heart condition before the age of 50
    • Currently smoke cigarettes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01937455

Layout table for location information
United Kingdom
Surrey Clinical Research Centre
Guildford, United Kingdom, GU2 7XP
Southampton Centre for Biomedical Research
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID)
Children's Hospital of Philadelphia
Layout table for investigator information
Principal Investigator: David JM Lewis Clinical Research Centre, Institute of Biosciences and Medicine, FHMS, University of Surrey
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: International AIDS Vaccine Initiative Identifier: NCT01937455    
Other Study ID Numbers: IAVI A003/CHOP HVDDT 001
2013-002268-14 ( EudraCT Number )
HHSN272201000021C ( Other Grant/Funding Number: NIH contract )
First Posted: September 9, 2013    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018
Keywords provided by International AIDS Vaccine Initiative:
HIV vaccine
HIV prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases